Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to advise that results from an independent study undertaken in collaboration with Tessara Therapeutics (“Tessara”) will be presented by the group’s Principal Scientist and Alzheimer’s Disease expert, Dr Mark Greenough at the AD/PD 2025 Advances in Sciences & Therapy conference on April 2nd to 3rd.